Myasthenia gravis self-administered questionnaire: development of regional domains

被引:18
作者
Padua, L
Galassi, G
Ariatti, A
Aprile, I
Caliandro, P
Evoli, A
Pazzaglia, C
Tonali, P
机构
[1] Univ Cattolica, Inst Neurol, I-00168 Rome, Italy
[2] Fdn Pro Iuventute, Ist Don C Iuventute, Rome, Italy
[3] Univ Hosp, Dept Neurol, Modena, Italy
关键词
myasthenia gravis; patient-oriented; SF-36; self-administered questionnaire; disease-specific questionnaire; domains; quality of life;
D O I
10.1007/s10072-004-0366-5
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
The objective was to develop regional domains from the Myasthenia Gravis Questionnaire (MGQ) to better assess generalised, bulbar and ocular involvement in patients with myasthenia gravis (MG) and to evaluate their responsiveness. Some items from the MGQ were aggregated into 3 domains: bulbar, generalised and ocular. The study was carried out at the Institute of Neurology, EMG Service, Universita Cattolica, Rome, and the Department of Neurology, University Hospital, Modena, Italy. Ninety-three MG patients were prospectively enrolled in two neurological departments; furthermore, outcome after treatment was studied in 23 patients to evaluate responsiveness. Disease severity was scored according to a modified version of the Osserman classification and MGQ. The questionnaire appeared more sensitive than clinical examination and history to assess bulbar and ocular involvement. For example, according to the bulbar domain, 67 patients experienced bulbar symptoms whereas on clinical examination 51 of 67 were completely normal in the bulbar region. The MGQ domains appeared reliable and sensitive. Results of global MG score (GMG) and of domains appeared reliable. Domains were able to better assess the functional involvement of anatomical regions than main GMG, clinical examination and history.
引用
收藏
页码:331 / 336
页数:6
相关论文
共 15 条
  • [1] OUTCOMES MEASUREMENTS - MORE QUESTIONS - SOME ANSWERS
    AMADIO, PC
    [J]. JOURNAL OF BONE AND JOINT SURGERY-AMERICAN VOLUME, 1993, 75A (11) : 1583 - 1584
  • [2] GUYATT GH, 1986, CAN MED ASSOC J, V134, P889
  • [3] HAWKER G, 1995, J RHEUMATOL, V22, P1193
  • [4] Hudak PL, 1996, AM J IND MED, V29, P602, DOI 10.1002/(SICI)1097-0274(199606)29:6<602::AID-AJIM4>3.0.CO
  • [5] 2-L
  • [6] Myasthenia gravis - Recommendations for clinical research standards
    Jaretzki, A
    Barohn, RJ
    Ernstoff, RM
    Kaminski, HJ
    Keesey, JC
    Penn, AS
    Sanders, DB
    [J]. NEUROLOGY, 2000, 55 (01) : 16 - 23
  • [7] OOSTERHUIS HJG, 1984, MYASTHENIA GRAVIS, pCH2
  • [8] OSSERMAN KE, 1971, MT SINAI J MED, V38, P497
  • [9] Myasthenia gravis outcome measure: development and validation of a disease-specific self-administered questionnaire
    Padua, L
    Evoli, A
    Aprile, I
    Caliandro, P
    Batocchi, AP
    Punzi, C
    Mazza, S
    Padua, R
    Tonali, P
    [J]. NEUROLOGICAL SCIENCES, 2002, 23 (02) : 59 - 68
  • [10] Health-related quality of life in patients with myasthenia gravis and the relationship between patient-oriented assessment and conventional measurements
    Padua, L
    Evoli, A
    Aprile, I
    Caliandro, P
    Mazza, S
    Padua, R
    Tonali, P
    [J]. NEUROLOGICAL SCIENCES, 2001, 22 (05) : 363 - 369